Incidence and clinical significance of adrenal masses in patients with gastrenteropancreatic neuroendocrine tumors Abstract #59

Introduction: The widespread application of modern imaging modalities, mainly computerized tomography (CT) and magnetic resonance imaging (MRI), has revealed a 2-3% incidence of inadvertently discovered adrenal masses, the majority of which are non-functioning benign adrenal adenomas. In the presence of a known malignancy, such lesions have a more than 30% incidence of being metastases. As patients with gastrenteropancreatic neuroendocrine tumors (GEP-NETS) have mainly well-differentiated and slow-growing tumors and are subject to routine abdominal imaging for disease staging or during follow-up, it is important to study the incidence and significance of such lesions based on the recently introduced TNM classification system.
Aim(s): To determine the incidence, character and follow-up of adrenal masses revealed by imaging in patients with various GEP-NETS and to relate them to clinical, biochemical, histopathological parameters.
Materials and methods: We retrospectively studied 115 patients with GEP-NETS (2005-2009) and recorded: gender, age at diagnosis, size and location of the primary tumor, stage and grading of the disease. Abdominal imaging was then evaluated for the presence of adrenal abnormalities, and monitored during the course of the disease and follow-up period (mean) by functional status assessment.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Georgios Kanakis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2798 Risk of Pre-Operative Understaging of Duodenal Neuroendocrine Tumors at Conventional Imaging: When Surgery Becomes the First Choice
Introduction: Duodenal neuroendocrine neoplasms (dNENs) are heterogeneous tumors that can exhibit aggressive behavior, with loco-regional nodes and distant metastases. Pre-treatment staging is the basis for planning either surgical or endoscopic treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: dr Sara Massironi
#2987 68Ga-DOTATOC PET/CT as Tool for Diagnosis and Decision-Making Process of Neuroendocrine Tumors
Introduction: Primary tumors in some patients with metastatic neuroendocrine tumors (NET) cannot be found by conventional imaging as CT, MRI and scintigraphy. 68Ga-DOTATOC PET/CT (68Ga-PET) appears to have superior sensitivity, specifity, and better resolution than 99mTC-octreotide SPECT/TC (SSTR scintigraphy) and can improve decision-making process, however its cost is higher, and its availability is limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Inmaculada Peiró Martínez
#2960 Epidemiological Characteristics of Neuroendocrine Tumors: A Retrospective Analysis of a Single Centre
Introduction: Neuroendocrine tumors (NETs) are a small heterogeneous group of cancers, developing from the neuroendocrine system. NETs may include functional or non-functional tumors; moreover, they may be familial and have further associated tumors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Ivana Puliafito
#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs
Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Stavroula Antoniou
#2879 Lung Neuroendocrine Tumors: Experience of Medical Oncology Department of Hospital 1st November 1954 Oran
Introduction: Lung neuroendocrine tumors account for 25% of all neuroendocrine tumors. It is a heterogeneous group that meets morphological criteria; immunohistochemical and molecular; defining 4 groups: Typical and atypical carcinoid tumors, neuroendocrine carcinomas with large cell and small cells. Carcinoid syndrome is rare in these tumors and the treatment is based on surgery for localized forms and multimodal treatment for metastatic forms.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Hakima Kehili